Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report report published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $32.00 target price on the stock.

CMPX has been the topic of a number of other research reports. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Guggenheim initiated coverage on Compass Therapeutics in a report on Monday. They set a “buy” rating and a $12.00 price objective on the stock. Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Stock Down 4.5 %

NASDAQ CMPX opened at $2.97 on Tuesday. The firm has a market cap of $408.64 million, a P/E ratio of -8.03 and a beta of 1.17. The company’s 50 day moving average is $2.49 and its 200-day moving average is $1.92. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $4.08.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MPM Bioimpact LLC increased its holdings in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC purchased a new position in Compass Therapeutics in the fourth quarter worth $11,293,000. Tang Capital Management LLC raised its position in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in Compass Therapeutics by 2.7% during the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock worth $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its holdings in shares of Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock worth $4,284,000 after purchasing an additional 75,000 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.